Alexza Pharmaceuticals
Alexza Pharmaceuticals, Inc. is a pharmaceutical company based in Mountain View, California, dedicated to the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions. The company utilizes its innovative Staccato system, a hand-held inhaler that vaporizes drugs into a condensation aerosol for rapid systemic delivery when inhaled. Its primary product, ADASUVE, contains Staccato loxapine and is intended for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Additionally, Alexza is developing AZ-002, which is Staccato alprazolam for acute repetitive seizures, and AZ-007, Staccato zaleplon for insomnia. The company was founded in 2001 and was formerly known as Alexza Molecular Delivery Corporation before rebranding in 2005. As of 2016, it operates as a subsidiary of Ferrer Therapeutics, Inc.
Symphony Allegro
Acquisition in 2009
Symphony Allegro is a biotechnology company focused on the development of innovative treatments for mental health conditions. It was established through a partnership between Symphony Capital Partners and Alexza Pharmaceuticals to advance specific pharmaceutical products, notably AZ-002 and AZ-004. The company is currently engaged in supporting AZ-004 in Phase III clinical trials aimed at treating acute agitation in patients diagnosed with schizophrenia and bipolar disorder. Additionally, Symphony Allegro is involved in the development of AZ-104, which is undergoing Phase IIa clinical trials for migraine treatment, and AZ-002, which is in Phase IIb clinical trials for addressing panic attacks in individuals with panic disorder. Through these efforts, Symphony Allegro aims to enhance therapeutic options for patients suffering from these challenging conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.